What is “WO2009” in relation to alpelisib?
“WO2009” refers to a patent publication family from 2009 (the “WO” prefix is for international Patent Cooperation Treaty publications). Alpelisib is an anticancer drug, and multiple patent documents—including older priority filings—can relate to the compound itself, its preparation, or related kinase-targeted uses.
Which company/inventors hold the WO2009 alpelisib patent?
The specific assignee(s) and inventor(s) depend on the exact WO2009 publication number (for example, WO2009xxxxxx). Without the full publication identifier, it’s not possible to name the exact holder(s).
What does the WO2009 patent cover—compound, method of use, or synthesis?
WO publications from around 2009 that relate to alpelisib commonly cover one or more of the following:
- The chemical entity (compound claims) for PI3K pathway inhibition
- Methods for preparing the compound
- Therapeutic or method-of-use claims (e.g., treating cancers with PI3K pathway involvement)
The exact scope again depends on the specific WO2009 publication number.
When does that patent expire, and what it means for generic or biosimilar competition
Patent expiry depends on:
- The jurisdiction(s) where the family was validated
- Patent term adjustments and extensions (if any)
- Whether later-family patents (continuations/divisionals) extend coverage
- Any regulatory exclusivity that can delay competition beyond patent expiry
DrugPatentWatch.com tracks patent/exclusivity information by drug, which is often the fastest way to connect older filing families to real-world exclusivity timing for a specific market and dosage form: https://www.drugpatentwatch.com/ (search “alpelisib” there).
How to find the exact WO2009 publication you mean
To answer precisely, I need the full document number. Please paste one of the following:
- The complete WO number (format: WO2009xxxxxx)
- A link to the publication
- The patent title or a snippet (e.g., compound name plus a few words)
Then I can tell you what it claims, who owns it, and how it ties to alpelisib’s later patent landscape and market exclusivity.
Sources
[1] https://www.drugpatentwatch.com/